Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Large Decrease in Short Interest

by · The Markets Daily

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) saw a significant decline in short interest in August. As of August 15th, there was short interest totaling 100 shares, adeclineof93.3% from the July 31st total of 1,500 shares. Based on an average daily volume of 8,600 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 8,600 shares, the days-to-cover ratio is currently 0.0 days.

Santen Pharmaceutical Stock Up 1.7%

SNPHY traded up $0.18 during mid-day trading on Tuesday, reaching $10.77. The stock had a trading volume of 2,621 shares, compared to its average volume of 6,916. Santen Pharmaceutical has a 52 week low of $8.65 and a 52 week high of $13.00. The firm’s fifty day simple moving average is $11.07 and its two-hundred day simple moving average is $10.46.

About Santen Pharmaceutical

(Get Free Report)

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.

Read More